Skip to main content

Aurobindo receives FDA approval for 3 generics

The company received approval for solifenacin succinate tablets, ranolazine extended-release tablets and sildenafil for oral suspension.
generic pills

Aurobindo Pharma Limited said the United States Food and Drug Administration has granted it approval for its abbreviated new drug application for solifenacin succinate tablets in 5 mg and 10 mg.

The solifenacin succinate tablets are an AB-rated generic equivalent to VESIcare tablets, and are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency,

A second approval was granted for the company's ranolazine extended-release tablets in 500 mg and 100 mg strengths.

[Read more: Aurobindo obtains FDA OK for 2 generics]

Ranolazine extended-release tablets are an AB-rated generic equivalent to Ranexa, and are indicated for the treatment of chronic angina.

Lastly, Aurobindo received approval for sildenafil for oral suspension in 10 mg/ML, a generic equivalent to Revatio.

Sildenafil for oral suspension is indicated for the treatment of pulmonary arterial hypertension in adults to improve exercise ability and delay clinical worsening.

X
This ad will auto-close in 10 seconds